


SYMANSIS™

Product Data Sheet

Compound Name

Tandutinib

Structure



CAS Number

[387867-13-2]

Chemical Formula:

C₃₁H₄₂N₆O₄

Molecular Weight:

562.7

Background information

Mode of Action	tyrosine kinases inhibitor
Predominant Target(s)	FLT3, PDGF, cKit
Published Activity (not validated)	treated in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome
Development stage	Phase I clinical trial

References

1. *Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro.* N. Brownlow, M. Vaid, N.J. Dibb. **Leukemia**. **22(7)**, 1452-1453 (2008)
2. *Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.* D.J. DeAngelo, R.M. Stone, M.L. Heaney, S.D. Nimer, R.L. Paquette, R.B. Klisovic, M.A. Caligiuri, M.R. Cooper, J.M. Lecerf, M.D. Karol, S. Sheng, N. Holford, P.T. Curtin, B.J. Druker, M.C. Heinrich. **Blood**. **108(12)**, 3674-3681 (2006)